Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q1 2025 Earnings Presentation
14 slides from Crinetics Pharmaceuticals's earnings presentation, May 8, 2025
Slide 1: First Quarter 2025 Financial Results and Business Update
May 8, 2025 First Quarter 2025 Financial Results and Business Update
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Su
Slide 3: Crinetics Has Never Been Stronger
Crinetics Has Never Been Stronger First anticipated Deep pipeline with World-class R&D IP rights commercial launch 2 late-stage programs in capabilities, 4 candidates into 2040s this year 4 indications in preclinical $1.3B of cash, cash Extensive internal Corporate dedication to equivalents & endocr
Slide 4: Preparing for a Successful Launch of Paltusotine
Preparing for a Successful Launch of Paltusotine Building Strong Increasing Education Paltusotine: PDUFA Date Foundational Infrastructure and Awareness of September 25, 2025 …for paltusotine and the MSLs in the field visiting pipeline in the US and globally endocrinologists Field force in place
Slide 5: CrinetiCARE and Other Patient Resources Launched to Support the Acromegaly Community
CrinetiCARE and Other Patient Resources Launched to Support the Acromegaly Community Patient Support Hub Disease State Education EDUCATE ENGAGE EMPOWER 5
Slide 6: Compelling Value Proposition for Paltusotine
Compelling Value Proposition for Paltusotine Faster Disease Control Titration to optimal level in weeks Reduce Treatment Burden Injectable SRLs difficult to administer Maintain Symptom Control Limit breakthrough symptoms Improve Patient Adherence Once-daily oral dosing Paltusotine is an investigatio
Slide 7: Updated Design and Status: Phase 2 Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Updated Design and Status: Phase 2 Atumelnant in Congenital Adrenal Hyperplasia (CAH) Treatment Arms: Key Eligibility Criteria • 4 cohorts, each 12 weeks (N=6-12) N=34-40 • Male or female 80 mg Once Daily (PM Dosing) (n=11) participants ≥18 to 75 years. Age: ≥16 years (US) 40 mg Once Daily (PM Dosin
Slide 8: Global Phase 3 CAH Trial Designed to Assess Normalization of Androgen and Glucocorticoids
Global Phase 3 CAH Trial Designed to Assess Normalization of Androgen and Glucocorticoids Key Eligibility Criteria (N = 150): • Male or female participants ≥ 18 to 75 years. • A4 > ULN1 with supraphysiologic GC dose (≥11 mg/m2/day) • Classic 21-hydroxylase deficiency • A4 > ULN1 with physiologic GC
Slide 9: Establishing Uncompromising CAH Treatment Goals
Establishing Uncompromising CAH Treatment Goals Androgen and GC Establishing the uncompromising treatment goal of normal adrenal androgens (A4 ≤ULN) Normalization with physiologic glucocorticoid replacement Early and extended period for glucocorticoid reduction designed to achieve GC as Replacement,
Slide 10: Continued Value Creation with Deep Pipeline of Transformative Drug Candidates
Continued Value Creation with Deep Pipeline of Transformative Drug Candidates Program Discovery IND-Enabling Phase 1 Phase 2 Phase 3 Registrational Upcoming Milestones Acromegaly (US) PDUFA Date (September 2025) Paltusotine (SST2 agonist) Acromegaly (EU) CHMP Opinion (1H 2026) Carcinoid syndrome Pha
Slide 11: Financial Results
Financial Results Three months ended March 31, (in millions) 2025 2024 Revenues $ 0.4 $ 0.6 R&D Expenses (76.2) (53.3) SG&A Expenses (35.5) (20.8) Net Loss $(96.8) $(66.9) Common Stock 93.7 million¹ 78.9 million² Outstanding 11 ¹ Shares of common stock outstanding as of May 2, 2025 ² Shares of com
Slide 12: $1.3 Billion Cash Balance Funds Current Operating Plan into 2029
$1.3 Billion Cash Balance Funds Current Operating Plan into 2029 $1.3 Billion Supports Strategic Initiatives Including: Cash, cash equivalents, & investments as of March 31, 2025 Anticipated launch of paltusotine and commercial infrastructure build Into 2029 Cash runway based on current operating
Slide 13: Serving our Patients
Serving our Patients Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives Ellen K. Acromegaly Patient 13
Slide 14: THANK YOU
| THANK YOU ‘Crinetics Pharmaceuticals
Crinetics Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix